Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

SNK01 / NKMAX

NCT04464967: Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Withdrawn

1/2

SNK01, Trastuzumab, Herceptin, Cetuximab, Erbitux

NKGen Biotech, Inc.

Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, Esophageal Cancer, Ovarian Cancer, Endometrium Cancer, Bladder Cancer, Pancreatic Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cervical Cancer, Sarcoma

08/22

02/23

SNK_ASTER, NCT04872634: A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Recruiting

1/2

RoW

SNK01 (Super Natural Killer Cells 01), GC, Cytotoxic Chemotherapy, Cetuximab

NKMAX Co., Ltd.

Non-small Cell Lung Cancer

05/23

NCT06189963: Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Recruiting

1/2

SNK01, Placebo

NKGen Biotech, Inc.

Moderate Alzheimer Disease

12/24

06/25

NCT05099549: Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Terminated

1/2

AFM24, SNK01

NKGen Biotech, Inc., Affimed GmbH

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor

09/23



	Diseases Companies Products Productz Mechanisms of Action Sites